PMID- 22614981 OWN - NLM STAT- MEDLINE DCOM- 20121112 LR - 20211021 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 30 IP - 19 DP - 2012 Jul 1 TI - Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. PG - 2334-9 LID - 10.1200/JCO.2011.41.1975 [doi] AB - PURPOSE: Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. PATIENTS AND METHODS: Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. RESULTS: One thousand seven hundred fifty-eight patients (5.2%) were younger than 40 years, 5,817 patients (17.3%) were younger than 50 years, and only 299 patients (0.9%) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. CONCLUSION: Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria. FAU - Hubbard, Joleen AU - Hubbard J AD - Mayo Clinic, Rochester, MN, USA. FAU - Thomas, David M AU - Thomas DM FAU - Yothers, Greg AU - Yothers G FAU - Green, Erin AU - Green E FAU - Blanke, Charles AU - Blanke C FAU - O'Connell, Michael J AU - O'Connell MJ FAU - Labianca, Roberto AU - Labianca R FAU - Shi, Qian AU - Shi Q FAU - Bleyer, Archie AU - Bleyer A FAU - de Gramont, Aimery AU - de Gramont A FAU - Sargent, Daniel AU - Sargent D LA - eng GR - CA37377/CA/NCI NIH HHS/United States GR - U10 CA069651/CA/NCI NIH HHS/United States GR - CA69974/CA/NCI NIH HHS/United States GR - U10 CA069974/CA/NCI NIH HHS/United States GR - CA69651/CA/NCI NIH HHS/United States GR - U10 CA037377/CA/NCI NIH HHS/United States GR - U10 CA012027/CA/NCI NIH HHS/United States GR - U24 CA114732/CA/NCI NIH HHS/United States GR - CA12027/CA/NCI NIH HHS/United States GR - CA25225/CA/NCI NIH HHS/United States GR - CA114732/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120521 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Chemotherapy, Adjuvant MH - Clinical Trials, Phase III as Topic MH - Colonic Neoplasms/*drug therapy/pathology/surgery MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Randomized Controlled Trials as Topic MH - Survival Rate MH - Treatment Outcome PMC - PMC3675692 COIS- Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. EDAT- 2012/05/23 06:00 MHDA- 2012/11/13 06:00 PMCR- 2013/07/01 CRDT- 2012/05/23 06:00 PHST- 2012/05/23 06:00 [entrez] PHST- 2012/05/23 06:00 [pubmed] PHST- 2012/11/13 06:00 [medline] PHST- 2013/07/01 00:00 [pmc-release] AID - JCO.2011.41.1975 [pii] AID - 11975 [pii] AID - 10.1200/JCO.2011.41.1975 [doi] PST - ppublish SO - J Clin Oncol. 2012 Jul 1;30(19):2334-9. doi: 10.1200/JCO.2011.41.1975. Epub 2012 May 21.